Results 31 to 40 of about 44,923 (207)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer

BMC Gastroenterology, 2018
Background For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis ...
Liuting Yang, Xiaoyue Jiang, Han Yan, Yingying Li, Hongchao Zhen, Bingmei Chang, Seyed Kariminia, Qin Li   +7 more
doaj   +1 more source

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity

Cancer Medicine, 2023
Objective Irinotecan is a useful anticancer drug for colorectal cancer treatment. UGT1A1*28 and *6 gene polymorphisms are known risk factors for irinotecan‐associated toxicity.
Kou Kanesada, Ryouichi Tsunedomi, Shoichi Hazama, Hiroyuki Ogihara, Yoshihiko Hamamoto, Yoshitaro Shindo, Hiroto Matsui, Yukio Tokumitsu, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Tatsuya Ioka, Hiroaki Nagano   +13 more
doaj   +1 more source

Protective role of Lactobacillus plantarum A7 against irinotecan-induced genotoxicity [PDF]

Avicenna Journal of Phytomedicine, 2016
Objective: Irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. The present study evaluated the effect of Lactobacillus plantarum A7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell ...
Soheila Sepahi, Abbas Jafarian-Dehkordi, Maryam Mirlohi, kobra shirani, Mahmoud Etebari   +4 more
doaj  

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications, 2019
Background The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational ...
Yuankai Shi, Jin Li, Jianming Xu, Yan Sun, Liwei Wang, Ying Cheng, Wei Liu, Guoping Sun, Yigui Chen, Li Bai, Yiping Zhang, Xiaohui He, Yi Luo, Zhehai Wang, Yunpeng Liu, Qiang Yao, Yuhong Li, Shukui Qin, Xiaohua Hu, Feng Bi, Rongsheng Zheng, Xuenong Ouyang   +21 more
doaj   +1 more source

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity

Frontiers in Reproductive Health, 2022
Background:Gonadal toxicity following chemotherapy is an important issue among the population of young cancer survivors. The inhibitor of DNA topoisomerase I, irinotecan (CPT-11), is widely used for several cancer types.
Mattan Levi, Mattan Levi, Irit Ben-Aharon, Irit Ben-Aharon, Ruth Shalgi   +4 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report

Clinical Medicine Insights: Case Reports, 2023
Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms.
Yu-Ting Shun, Hsien-Yung Lai, Yi-Ting Chuang, Hsuen-Fu Lin   +3 more
doaj   +1 more source

The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice

Pharmaceuticals, 2020
Irinotecan, an anticancer drug, induces diarrhea and intestinal inflammation, resulting in an increase in the cost of care and in treatment delays.
Daniely V. S. Costa, Deiziane V. S. Costa, Caren N. S. Sousa, Angeline M. H. P. Silva, Ingridy S. Medeiros, Dainesy S. Martins, Conceição S. Martins, Ana L. V. Pequeno, Roberto C. P. Lima-Júnior, Pedro M. G. Soares, Silvânia M. M. Vasconcelos, Gerly A. C. Brito, Emmanuel P. Souza   +12 more
doaj   +1 more source

Effect of echinacoside as a palliative for irinotecan-induced intestinal mucositis

Интегративная физиология, 2023
Irinotecan, an anticancer drug, causes severe delayed diarrhea due to its active metabolite, SN-38, which damages the intestinal mucosa. This diarrhea may lead to the discontinuation of anticancer therapy in clinical practice.
Хикару Оцуки, Шизука Джонан, Тайсэй Цудзии, Нахла Хамуда, Кикуко Амагазе   +4 more
doaj   +1 more source

Impact of omega 3 alone or in combination with irinotecan on bone marrow and spleen of rats: in vivo study

Iraqi Journal of Pharmaceutical Sciences, 2023
Objectives: The present study designed to explore the genotoxicity through measurement of Mitotic index in bone marrow and the spleen cells, as possible mechanism of bone marrow and spleen toxicity that induced by irinotecan; and to describe the ...
Alaa Radhi, Nada Al-Shawi, Ali Hassan
doaj   +1 more source